Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter Future
Authors:
- 1 October 2021
- journal article
- review article
- Published by Elsevier in Neurotherapeutics
- Vol. 18 (4) , 2286-2302
Abstract
No abstract availableKeywords
This publication has 121 references indexed in Scilit:
- Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathyJournal of Neurology, 2013
- Fibroblasts endocytose and degrade transthyretin aggregates in transthyretin-related amyloidosisLaboratory Investigation, 2013
- AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretinProceedings of the National Academy of Sciences, 2013
- Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascadeProceedings of the National Academy of Sciences, 2012
- Evidence for a Functional Role of the Molecular Chaperone Clusterin in Amyloidotic CardiomyopathyThe American Journal of Pathology, 2011
- Tetracycline and its analogues protect Caenorhabditis elegans from β amyloid-induced toxicity by targeting oligomersNeurobiology of Disease, 2010
- Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse modelsJournal of Translational Medicine, 2010
- Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice modelThe FASEB Journal, 2006
- Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene diseaseHuman Molecular Genetics, 2005
- Tetramer Dissociation and Monomer Partial Unfolding Precedes Protofibril Formation in Amyloidogenic Transthyretin VariantsJournal of Biological Chemistry, 2001